Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 2,671 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control II Clear all

Conditions: HIV Infections
Interventions: VGX-410 (Mifepristone), Placebo for VGX-410 (Mifepristone); Drug
Lead sponsor: VGX Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 1 more

Conditions: Biliary Tract Cancer
Interventions: Atezolizumab, Bevacizumab, Placebo, Cisplatin, Gemcitabine; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Duarte, California • Boston, Massachusetts • Durham, North Carolina + 2 more

Conditions: Bipolar Depression
Interventions: Infliximab, Saline; Drug · Other
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Pediatric Obesity, Obesity
Interventions: Healthy Caregivers- Healthy Children Toolkit, Safety Curriculum; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 2 Years to 5 Years
Enrollment: 2,289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Upper Extremity Paresis
Interventions: transcranial direct current stimulation; Device
Lead sponsor: University of the Sciences in Philadelphia; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Autism Spectrum Disorder (ASD)
Interventions: Placebo, RO7017773; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 15 Years to 45 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Phoenix, Arizona • New Haven, Connecticut • Orlando, Florida + 8 more

Conditions: Major Depressive Disorder, Bipolar Disorder II
Interventions: Electroconvulsive Therapy; Procedure
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: T2DM With Inadequate Glycemic Control
Interventions: CS02 tablet and placebo tablet; Drug
Lead sponsor: Center Laboratories, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Little Rock, Arkansas • Coral Gables, Florida • Hialeah, Florida

Conditions: Neovascular Age Related Macular Degeneration
Interventions: Squalamine lactate, Vehicle control; Drug
Lead sponsor: Ohr Pharmaceutical Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 20
States / cities: Tucson, Arizona • Bakersfield, California • Beverly Hilss, California + 17 more

Conditions: Health Harming Legal Needs
Interventions: Critical Time Medical-Legal Partnership Intervention; Other
Lead sponsor: Stony Brook University; Other
Eligibility: 13 Years and older
Enrollment: 1,140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure
Interventions: Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more

Conditions: Ankle Fracture
Interventions: Ibuprofen, Acetaminophen/hydrocodone; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: counseling intervention, educational intervention, survey administration, psychosocial assessment and care, supportive care; Other · Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 8 Years to 120 Years · Female only
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts

Conditions: Age-related Macular Degeneration
Interventions: Ranibizumab 0.5mg; Drug
Lead sponsor: Southern California Desert Retina Consultants, MC; Other
Eligibility: 50 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: Mountain View, California • Palm Desert, California • Baltimore, Maryland + 1 more

Conditions: Covid19
Interventions: Silmitasertib, SOC; Drug
Lead sponsor: Senhwa Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Gainesville, Georgia

Conditions: Type 2 Diabetes Mellitus
Interventions: AC-201, 25mg, AC-201, 50mg, AC-201, 75mg, Placebo; Drug
Lead sponsor: TWi Biotechnology, Inc.; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 13
States / cities: Chino, California • Los Angeles, California • Coral Gables, Florida + 10 more

Conditions: Parvovirus B19 Infection
Interventions: VAI-VP705 (parvovirus B-19 vaccine), Placebo, MF-59; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas

Conditions: Colorectal Neoplasms
Interventions: KD018, Irinotecan, Placebo; Drug
Lead sponsor: Edward Chu, MD; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: New Haven, Connecticut • Pittsburgh, Pennsylvania

Conditions: Clostridium Difficile Infection
Interventions: SMT19969, Vancomycin; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 24
States / cities: Mobile, Alabama • Laguna Hills, California • Long Beach, California + 21 more

Conditions: Cancer
Interventions: Fentanyl sublingual spray, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Cavities of Teeth, Dental Decay
Interventions: Scotchbond™ Universal Plus Adhesive, Scotchbond™ Universal Adhesive; Device
Lead sponsor: Solventum US LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Congestive Heart Failure
Interventions: Oxypurinol; Drug
Lead sponsor: Advanz Pharma; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 4
States / cities: Oceanside, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Opioid Withdrawal
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Miami Lakes, Florida • Marlton, New Jersey • New York, New York

Search by objective public record fields.

Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects

A Study of Viracept in HIV-Positive Women

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

Healthy Caregivers-Healthy Children (HC2) Phase II

Priming With tDCS: Expanding the Window of Recovery in Chronic Stroke

A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

Long-term Potentiation Disruption Underlying Cognitive Impairment in ECT

CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)

Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

NSAIDS Versus Opioids in Acute SER II Ankle Fractures

Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

B-19 Parvovirus Vaccine Study

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Scotchbond Universal Plus Compared to Scotchbond Universal for Posterior Class I & II Restorations With Filtek Universal

Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal